GlassScriptPhysician profile
Nhat Q Nguyen
NPI 1053643072
$5,614.82
in general payments reported to CMS, 2019-2025
24 companies · $690 in 2025
The $690 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $427 · 2021: $815 · 2022: $1,097 · 2023: $1,055 · 2024: $621 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,739.81 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $495.28 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $473.02 | 2020-2025 | Entyvio, Eohilia |
| Medtronic, INC. | $294.71 | 2021-2022 | |
| Braintree Laboratories, INC. | $284.22 | 2019-2025 | Suflave, Sutab |
| Janssen Biotech, INC. | $187.63 | 2019-2025 | Simponi Aria, Stelara, Simponi |
| Redhill Biopharma INC. | $176.02 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $148.61 | 2019-2023 | Linzess |
| Allergan, INC. | $133.59 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $129.99 | 2021-2023 | Clenpiq |
| Ardelyx, INC. | $91.57 | 2024-2025 | Ibsrela |
| Boston Scientific Corporation | $88.04 | 2022 | |
| Gilead Sciences, INC. | $51.30 | 2021-2024 | |
| Nestle Healthcare Nutrition INC. | $50.80 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $42.89 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $36.10 | 2022-2025 | |
| Madrigal Pharmaceuticals | $34.82 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $30.68 | 2024-2025 | Voquezna |
| Celgene Corporation | $30.16 | 2021 | |
| Alnylam Pharmaceuticals INC. | $28.21 | 2025 | Givlaari |
| Regeneron Healthcare Solutions, INC. | $25.30 | 2025 | Dupixent |
| Intra-Sana Laboratories | $15.73 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Evoke Pharma, INC. | $14.41 | 2025 | |
| Daiichi Sankyo INC. | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nhat Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.